Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 311
Filtrar
1.
Tech Coloproctol ; 28(1): 56, 2024 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-38772962

RESUMEN

BACKGROUND: Rectal neuroendocrine tumors (rNET) are rare and challenging to manage. While most patients with small rNET can be definitively treated with local excision, the role of chemotherapy in general and neoadjuvant therapy particularly in managing advanced rNET has not been well established. Therefore, this study aimed to determine which patients with rNET may gain a survival benefit from neoadjuvant chemotherapy. METHODS: A retrospective cohort analysis of all patients who underwent surgical resection of rNET in the US National Cancer Database (NCDB) (2004-2019) was performed. First, univariate and multivariate Cox regression analyses were performed to determine the independent predictors of poor overall survival (OS) and define the high-risk groups. Afterward, stratified OS analyses were performed for each high-risk group to assess whether neoadjuvant chemotherapy had a survival benefit in each group. RESULTS: A total of 1837 patients (49.8% female; mean age 56.6 ± 12.3 years) underwent radical resection of a rNET. Tumors > 20 mm in size, clinical T4 tumors, poorly differentiated tumors, and metastatic disease were independent predictors of worse OS and were defined as high-risk groups. Neoadjuvant chemotherapy did not have a significant survival benefit in any of the high-risk groups, except for patients with high-grade rNETs where neoadjuvant therapy significantly improved OS to a mean of 30.9 months compared with 15.9 months when neoadjuvant therapy was not given (p = 0.006). CONCLUSIONS: Neoadjuvant chemotherapy improved the OS of patients with high-grade rNET by 15 months and may be indicated for this group.


Asunto(s)
Bases de Datos Factuales , Terapia Neoadyuvante , Tumores Neuroendocrinos , Neoplasias del Recto , Humanos , Terapia Neoadyuvante/estadística & datos numéricos , Terapia Neoadyuvante/métodos , Neoplasias del Recto/terapia , Neoplasias del Recto/patología , Neoplasias del Recto/mortalidad , Neoplasias del Recto/cirugía , Femenino , Persona de Mediana Edad , Masculino , Estudios Retrospectivos , Tumores Neuroendocrinos/terapia , Tumores Neuroendocrinos/mortalidad , Tumores Neuroendocrinos/cirugía , Tumores Neuroendocrinos/tratamiento farmacológico , Anciano , Estados Unidos , Quimioterapia Adyuvante/estadística & datos numéricos , Adulto , Resultado del Tratamiento
2.
Tech Coloproctol ; 27(10): 787-797, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37150800

RESUMEN

PURPOSE: Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and perineal procedures for rectal prolapse in terms of recurrence, complications, and improvement in fecal incontinence (FI). METHODS: A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were included. The risk of bias was assessed using the ROB-2 tool. The main outcomes were recurrence of full-thickness rectal prolapse, complications, operation time, and improvement in FI. RESULTS: Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altemeier procedure (logOR, - 12.75; 95% credible intervals, - 40.91, - 1.75), Delorme procedure (- 13.10; - 41.26, - 2.09), resection rectopexy (- 11.98; - 41.36, - 0.19), sponge rectopexy (- 13.19; - 42.87, - 0.54), and sutured rectopexy (- 13.12; - 42.58, - 1.50), but similar odds to ventral mesh rectopexy (- 12.09; - 41.7, 0.03). Differences among the procedures in complications, operation time, and improvement in FI were not significant. CONCLUSIONS: Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates.


Asunto(s)
Procedimientos Quirúrgicos del Sistema Digestivo , Incontinencia Fecal , Laparoscopía , Prolapso Rectal , Humanos , Prolapso Rectal/cirugía , Prolapso Rectal/complicaciones , Metaanálisis en Red , Laparoscopía/métodos , Recto/cirugía , Procedimientos Quirúrgicos del Sistema Digestivo/efectos adversos , Incontinencia Fecal/cirugía , Incontinencia Fecal/complicaciones , Mallas Quirúrgicas/efectos adversos , Recurrencia , Resultado del Tratamiento , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Tech Coloproctol ; 27(6): 429-441, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36479654

RESUMEN

BACKGROUND: Patients with refractory fecal incontinence symptoms can be treated with several surgical procedures including graciloplasty. Reported outcomes and morbidity rates of this procedure are highly variable. The aim of this study was to assess continence rate and safety of dynamic and adynamic graciloplasty. METHODS: PubMed and Google Scholar databases were systematically searched from inception until January 2022 according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Reviews, animal studies, studies with patients < 18 years or < 10 patients, with no success rate reported or non-English text, were excluded. Main outcome measures were overall continence and morbidity rates of each technique. RESULTS: Fourteen studies were identified, incorporating a total of 450 patients (337 females), published between 1980 and 2021. Most common etiology of incontinence (35.5%-n = 160) was obstetric trauma followed by anorectal trauma (20%-n = 90). The weighted mean rate of continence after dynamic graciloplasty was 69.1% (95% CI 0.53-0.84%, I2 = 90%) compared to 71% (95% CI 0.54-0.87, I2 = 82.5%) after adynamic. Although the weighted mean short-term complication rate was lower in the dynamic group (26% versus 40%), when focusing on complications requiring intervention under general anesthesia, there was a much higher incidence (43.4% versus 10.5%) in the dynamic group. The weighted mean rate of long-term complications was 59.4% (95% CI 0.13-1.04%, I2 = 97.7%) in the dynamic group, almost twice higher than in the adynamic group [30% (95% CI - 0.03 to 0.63), I2 = 95.8%]. Median follow-up ranged from 1 to 13 years. CONCLUSIONS: Our data suggest that graciloplasty may be considered for incontinent patients. Dynamic graciloplasty may harbor higher risk for reoperation and complications compared to adynamic. The fact that the functional results between adynamic and dynamic graciloplasty are equivalent and the morbidity rate of adynamic graciloplasty is significantly lower reinforce the graciloplasty as an option to treat appropriately selected patients with fecal incontinence.


Asunto(s)
Incontinencia Fecal , Procedimientos de Cirugía Plástica , Femenino , Animales , Humanos , Incontinencia Fecal/etiología , Incontinencia Fecal/cirugía , Incontinencia Fecal/diagnóstico , Resultado del Tratamiento , Canal Anal/cirugía , Procedimientos de Cirugía Plástica/efectos adversos , Reoperación
4.
Tech Coloproctol ; 27(4): 291-296, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36175722

RESUMEN

BACKGROUND: The aim of this study was to assess the effect of preoperative biologic therapy on the surgical outcome of Crohn's disease (CD) patients undergoing repeat ileocolic resection. METHODS: This was a retrospective analysis of all CD patients who underwent repeat ileocolic resection at Cleveland Clinic Florida between January 2011 and April 2021. Patients were divided into two groups: treatment biologic therapy prior to surgery and controls. RESULTS: Sixty-five patients (31males, median age 54 [range 23-82] years) were included in the study. Twenty nine (44.6%) were treated with biologic therapy prior to repeat ileocolic resection. No demographic differences were found between the biologic therapy and control groups. In addition, no differences were found in mean time from index ileocolic resection (p = 0.9), indication for surgery (p = 0.11), and preoperative albumin (p = 0.69). The majority of patients (57; 87.7%) were operated on laparoscopically, and mean overall operation time was 225 (SD 49.27) min. Overall, the postoperative complication rate was 43.1% (28 patients) and median length of stay was 5 (range 2-21) days. Postoperative complications were more common in the control group, compared to the biologic therapy group (55.6 vs 27.5%; p = 0.04). Conversion rate (35.7 vs 20.7%; p = 0.24), operation time (223 vs 219 min; p = 0.75), length of stay (5.2 vs 5.9 days; p = 0.4), and readmission (16.6 vs 11.1%; p = 0.72) were similar between the two groups. Multivariate analysis of risk factors for postoperative complications showed that biologic treatment was correlated with a lower risk (HR -0.28, CI 95% -0.5596 to -0.01898, p = 0.03). CONCLUSIONS: Patients treated with biologic therapy for CD who underwent repeat ileocolic resection had fewer postoperative complications.


Asunto(s)
Enfermedad de Crohn , Laparoscopía , Humanos , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Enfermedad de Crohn/cirugía , Estudios Retrospectivos , Intestinos/cirugía , Complicaciones Posoperatorias/cirugía , Terapia Biológica , Íleon/cirugía , Resultado del Tratamiento
5.
Tech Coloproctol ; 26(8): 637-643, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35451660

RESUMEN

BACKGROUND: The aim of the present study was to review the prevalence and surgical management of patients with Crohn's disease (CD) complicated by ileocolic-duodenal fistulas (ICDF). METHODS: We performed a retrospective chart review of CD patients who underwent surgical takedown and repair of ICDF during January 2011-December 2021 at two inflammatory bowel disease referral centers. RESULTS: We identified 17 patients with ICDF (1.3%) out of 1283 CD patients who underwent abdominal surgery. Median age was 42 (20-71) years, 13 patients were male (76%) and median body mass index was 22.7 (18.4-30.3) kg/m2. Four patients (24%) were diagnosed preoperatively and only 2 (12%) were operated on for ICDF-related symptoms. The most common procedure was ileocolic resection (13 patients, 76%) including 4 repeat ileocolic resections (24%). The duodenal defect was primarily repaired in all patients with no re-fistulization or duodenal stenosis, regardless of the repair technique. A laparoscopic approach was attempted in the majority of patients (14 patients, 82%); however, only 5 (30%) were laparoscopically completed. The overall postoperative complication rate was 65% including major complications in 3 patients (18%) and 2 patients (12%) who required surgical re-intervention for abdominal wall dehiscence and postoperative bleeding. Preoperative nutritional optimization was performed in 9 patients (53%) due to malnutrition. These patients had significantly less intra-operative blood loss (485 vs 183 ml, p = 0.05), and a significantly reduced length of stay (18 vs 8 days, p = 0.05). CONCLUSION: ICDF is a rare manifestation of CD which may go unrecognized despite the implementation of a comprehensive preoperative evaluation. Although laparoscopic management of ICDF may be technically feasible, it is associated with a high conversion rate. Preoperative nutritional optimization may be beneficial in improving surgical outcomes in this select group of patients.


Asunto(s)
Enfermedad de Crohn , Fístula Intestinal , Laparoscopía , Adulto , Colon/cirugía , Enfermedad de Crohn/complicaciones , Enfermedad de Crohn/cirugía , Femenino , Humanos , Íleon/cirugía , Fístula Intestinal/epidemiología , Fístula Intestinal/etiología , Fístula Intestinal/cirugía , Laparoscopía/métodos , Masculino , Complicaciones Posoperatorias/epidemiología , Prevalencia , Estudios Retrospectivos , Resultado del Tratamiento
6.
Tech Coloproctol ; 26(3): 181-186, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-35091791

RESUMEN

BACKGROUND: The purpose of this study was to review whether routine usage of indocyanine green (ICG) perfusion assessment during complex ileal J-pouch surgery requiring lengthening maneuvers reduces ischemic complications. METHODS: Retrospective chart review of patients with ulcerative colitis (UC) or familial adenomatous polyposis (FAP) who underwent ileal pouch-anal anastomosis (IPAA) surgery with lengthening maneuvers and intraoperative ICG assessment between January 2015 and January 2021. All patients underwent a double stapled anastomosis and were temporarily diverted. All patients underwent laparoscopic and trans-anal ICG assessment of their J-pouch and anastomosis. All J-pouches were evaluated 6 weeks after surgery via contrast enema and pouchoscopy. RESULTS: One hundred fifty eight patients underwent ileal J-pouch surgery during the study period. Sixteen patients (10%) underwent lengthening maneuvers and intra-operative ICG assessment. Twelve patients underwent surgery for UC and 4 for FAP. Median age was 40.3 years and average body mass index was 24.9 kg/m2. Twelve patients underwent a two-stage procedure and the remaining underwent a three-stage procedure. 93.7% of cases were completed laparoscopically (15/16). All patients underwent scoring of the peritoneum and 43% (7/16) underwent division of the ileocolic or intermediate mesenteric vessels. There was no mortality or pouch ischemia and the leak rate was 12.5%. All patients underwent reversal after an average of 18 ± 7 weeks. CONCLUSION: ICG perfusion assessment appears to be of utility in complex IPAA surgery requiring lengthening maneuvers. Its application may be associated with reduced J-pouch ischemia and leak rate in this unique setting.


Asunto(s)
Colitis Ulcerosa , Reservorios Cólicos , Proctocolectomía Restauradora , Adulto , Anastomosis Quirúrgica/efectos adversos , Colitis Ulcerosa/cirugía , Angiografía con Fluoresceína , Humanos , Verde de Indocianina , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/cirugía , Proctocolectomía Restauradora/efectos adversos , Proctocolectomía Restauradora/métodos , Estudios Retrospectivos , Resultado del Tratamiento
7.
Sci Rep ; 10(1): 914, 2020 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-31969609

RESUMEN

The in vitro production of blood platelets for transfusion purposes is an important goal in the context of a sustained demand for controlled products free of infectious, immune and inflammatory risks. The aim of this study was to characterize human platelets derived from CD34+ progenitors and to evaluate their hemostatic properties. These cultured platelets exhibited a typical discoid morphology despite an enlarged size and expressed normal levels of the major surface glycoproteins. They aggregated in response to ADP and a thrombin receptor agonist peptide (TRAP). After infusion into NSG mice, cultured and native platelets circulated with a similar 24 h half-life. Notably, the level of circulating cultured platelets remained constant during the first two hours following infusion. During this period of time their size decreased to reach normal values, probably due to their remodeling in the pulmonary circulation, as evidenced by the presence of numerous twisted platelet elements in the lungs. Finally, cultured platelets were capable of limiting blood loss in a bleeding assay performed in thrombocytopenic mice. In conclusion, we show here that cultured platelets derived from human CD34+ cells display the properties required for use in transfusion, opening the way to clinical trials.


Asunto(s)
Antígenos CD34 , Plaquetas/fisiología , Hemostasis , Agregación Plaquetaria , Transfusión de Plaquetas , Células Madre , Adenosina Difosfato/farmacología , Animales , Plaquetas/metabolismo , Células Cultivadas , Femenino , Glicoproteínas/metabolismo , Técnicas In Vitro , Ratones Transgénicos , Fragmentos de Péptidos/farmacología , Agregación Plaquetaria/efectos de los fármacos
8.
Sci Rep ; 8(1): 15808, 2018 10 25.
Artículo en Inglés | MEDLINE | ID: mdl-30361531

RESUMEN

Platelets are produced upon profound reorganization of mature megakaryocytes (MK) leading to proplatelet elongation and release into the blood stream, a process termed thrombopoiesis. This highly dynamic process requires microtubules (MT) reorganization by mechanisms that are still incompletely understood. Adenomatous polyposis coli (APC) is a microtubule plus-end tracking protein involved in the regulation of MT in a number of cell systems and its inactivation has been reported to alter hematopoiesis. The aim of our study was to investigate the role of APC in megakaryopoiesis and the final steps of platelet formation. Down-regulation of APC in cultured human MK by RNA interference increased endomitosis and the proportion of cells able to extend proplatelets (68.8% (shAPC1) and 52.5% (shAPC2) vs 28.1% in the control). Similarly an increased ploidy and amplification of the proplatelet network were observed in MK differentiated from Lin- cells of mice with APC-deficiency in the MK lineage. In accordance, these mice exhibited increased platelet counts when compared to wild type mice (1,323 ± 111 vs 919 ± 52 platelets/µL; n = 12 p 0.0033**). Their platelets had a normal size, ultrastructure and number of microtubules coils and their main functions were also preserved. Loss of APC resulted in lower levels of acetylated tubulin and decreased activation of the Wnt signaling pathway. Thus, APC appears as an important regulator of proplatelet formation and overall thrombopoiesis.


Asunto(s)
Proteína de la Poliposis Adenomatosa del Colon/metabolismo , Plaquetas/metabolismo , Microtúbulos/metabolismo , Acetilación , Proteína de la Poliposis Adenomatosa del Colon/deficiencia , Animales , Plaquetas/ultraestructura , Linaje de la Célula , Células Cultivadas , Megacariocitos/citología , Megacariocitos/metabolismo , Megacariocitos/ultraestructura , Ratones Endogámicos C57BL , Ratones Transgénicos , Microtúbulos/ultraestructura , Recuento de Plaquetas , Ploidias , Vía de Señalización Wnt
9.
Int J Colorectal Dis ; 31(9): 1649-51, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27392779

RESUMEN

PURPOSE: The purpose of this review is to highlight the perils and pitfalls associated with high vascular ligation during right colectomies for adenocarcinoma and to identify the various mechanisms of injury to the superior mesenteric vein (SMV) and its tributaries. METHODS: This is a retrospective chart review of 304 right colectomies (159 open and 145 laparoscopic) performed over a period of 10 years (1 June 2006-31 May 2016) for right-sided colonic adenocarcinoma in an academic medical center. RESULTS: During a 10-year study period, we encountered five cases in which significant damage to the SMV and its tributaries occurred. This accounts for a total of 1.6 % of all right colectomies performed for colonic adenocarcinoma. CONCLUSIONS: Iatrogenic superior mesenteric vein injury is a rare, severe, and underreported complication of both open and laparoscopic right colectomy for colonic adenocarcinoma. We identified several mechanisms of injury such as anatomic misperception, excessive traction and pulling on the venous system, extensive tumor involvement of the mesentery, and uncontrolled suturing attempts at hemostasis. We believe that increased awareness of this complication with profound understanding of vascular anatomy and the different mechanisms of injury will allow surgeons to avoid this often devastating complication.


Asunto(s)
Enfermedad Iatrogénica , Ligadura/efectos adversos , Venas Mesentéricas/lesiones , Humanos , Venas Mesentéricas/patología , Estudios Retrospectivos
10.
J Thromb Haemost ; 14(7): 1470-9, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27148783

RESUMEN

UNLABELLED: Essentials A signaling role of glycoprotein (GP)Ibß is postulated but not formally demonstrated in platelets. Lentiviral-mediated rescue in knock-out mice can be used to evaluate GPIbß function in vivo. Transduction of the native subunit corrected the main defects associated with GPIb-IX deficiency Deletion of intracellular 159-170 segment increased thrombosis, 150-160 removal increased bleeding. SUMMARY: Background The platelet glycoprotein (GP)Ib-V-IX complex is required for normal hemostasis and megakaryopoiesis. A role in GPIb-dependent responses has been ascribed to the less well characterized GPIbß subunit using a specific antibody and GPIb-IX transfected cells. Objectives Our aim was to evaluate, in vivo, the role of the GPIbß in hemostasis and thrombosis. Methods GPIbß(null) Sca-1(+) progenitors transduced with viral particles harboring hGPIbß were transplanted into lethally irradiated GPIbß(-/-) recipient mice. Results hGPIbß transplanted into the bone marrow of GPIbß(null) mice rescued GPIb-IX expression in 97% of circulating platelets. These platelets efficiently bound von Willebrand factor (VWF) and extended filopodia on a VWF matrix, demonstrating the restoration of GPIb-dependent adhesive and signaling properties. These mice exhibited less severe macrothrombocytopenia and had normal tail bleeding times as compared with GPIbß(null) mice. This strategy was employed to manipulate and evaluate the role of the GPIbß intracellular domain. Removal of the membrane proximal segment (Δ(150-160) ) decreased GPIb-IX expression by 43%, confirming its involvement in receptor assembly and biosynthesis, and resulted in increased bleeding times and decreased thrombosis in a mechanical injury model in the aorta. On the other hand, deletion of the C-flanking 159-170 segment allowed normal GPIb-IX expression, VWF-dependent responses and bleeding times, but resulted in enhanced arterial thrombosis. Conclusion This pointed to a repressor role of GPIbß in thrombus formation in vivo that was not predicted in studies of heterologous cells. These results highlight the utility of this lentiviral strategy for the structure-function evaluation of GPIb-IX in platelets.


Asunto(s)
Síndrome de Bernard-Soulier/genética , Técnicas de Transferencia de Gen , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Animales , Aorta/metabolismo , Tiempo de Sangría , Plaquetas/metabolismo , Células de la Médula Ósea/citología , Femenino , Eliminación de Gen , Regulación de la Expresión Génica , Vectores Genéticos , Células HEK293 , Hemorragia , Hemostasis , Humanos , Lentivirus , Masculino , Megacariocitos/citología , Ratones , Ratones Noqueados , Microscopía Electrónica de Rastreo , Dominios Proteicos , Trombosis/metabolismo , Transgenes , Factor de von Willebrand/metabolismo
11.
Artículo en Inglés | MEDLINE | ID: mdl-24940691

RESUMEN

Mechanisms of free radical injury involve chemical modification of proteins, lipid derivatives and nucleic acids and consequent loss of its function. However, specific targets and exact sequence of events has not been fully clarified. We determined whether extracellular enzymes that are involved in adenosine formation such as ecto-5'nucleotidase (e5N) and removal such as extracellular form of adenosine deaminase (eADA) could be affected by peroxynitrite. We used intact cell assay system that involves exposure of cultured HMEC-1 cells to substrates followed by HPLC analysis of conversion of substrates into products. We found that e5N and ADA activities decreased by 20-40% after incubation for 20 or 60 minutes with 30 µM peroxynitrite. Decrease of cellular ATP and NAD was also observed. We conclude that besides other cytotoxic effects modification of extracellular enzymes of nucleotide metabolism could be important target for free radical injury.


Asunto(s)
Células Endoteliales/citología , Espacio Extracelular/efectos de los fármacos , Espacio Extracelular/metabolismo , Nucleótidos/metabolismo , Ácido Peroxinitroso/farmacología , 5'-Nucleotidasa/metabolismo , Adenosina/metabolismo , Adenosina Desaminasa/metabolismo , Línea Celular , Espacio Extracelular/enzimología , Humanos , Estrés Fisiológico/efectos de los fármacos
12.
Eur Neuropsychopharmacol ; 24(2): 302-8, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23860355

RESUMEN

Aside from the well-known biologically active angiotensin II, other biologically active angiotensins have been discovered, including angiotensin IV and angiotensin-(1-7). Some years ago, we and others discovered that the Mas proto-oncogene encodes a G protein-coupled receptor being essential for angiotensin-(1-7) signaling. Mas is not only expressed in the periphery but also within the brain, e.g. in the dentate gyrus (DG) and the piriform cortex (PC). Since the DG is capable of adult neurogenesis, we examined the impact of a deletion of Mas upon adult neurogenesis. Deletion of Mas did not alter cell proliferation in the adult DG (as monitored with phosphohistone H3) and did not alter cell death (as monitored with activated Caspase 3). However, Mas deficiency resulted in an increase in the number of doublecortin (DCX) positive cells, indicating that lack of Mas increases the number of this cell population. Concerning the PC, it is discussed whether adult neurogenesis occurs under physiological conditions in this area. We could demonstrate that Mas deficiency has an impact on cell division and on the population of DCX-positive cells within the PC. Since Mas is not expressed before birth within the brain, our data may suggest that adult hippocampal neurogenesis and neurogenesis occurring during prenatal development share several common mechanisms, but are, at least in part, differentially regulated. Moreover, since deficiency for Mas increases the numbers of DCX-positive young neurons, blockage of Mas might be beneficial in stimulating neurogenesis in adults.


Asunto(s)
Giro Dentado/fisiología , Proteínas Asociadas a Microtúbulos/metabolismo , Neurogénesis , Neuropéptidos/metabolismo , Vías Olfatorias/fisiología , Proteínas Proto-Oncogénicas/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Animales , Apoptosis/fisiología , Caspasa 3/metabolismo , División Celular/fisiología , Proliferación Celular , Proteínas de Dominio Doblecortina , Proteína Doblecortina , Histonas/metabolismo , Inmunohistoquímica , Ratones , Ratones Noqueados , Neuronas/fisiología , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/genética , Receptores Acoplados a Proteínas G/genética
13.
Oncogene ; 33(40): 4803-12, 2014 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-24141787

RESUMEN

Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.


Asunto(s)
Proteína BRCA2/metabolismo , Neoplasias de la Mama/genética , Reparación del ADN , Proteínas de Unión al ADN/metabolismo , Proteínas Nucleares/genética , Recombinasa Rad51/metabolismo , Proteínas Supresoras de Tumor/genética , Proteína BRCA2/química , Roturas del ADN de Doble Cadena , Proteínas de Unión al ADN/química , Proteína del Grupo de Complementación N de la Anemia de Fanconi , Femenino , Células HEK293 , Células HeLa , Humanos , Mutación Missense , Proteínas Nucleares/química , Proteínas Nucleares/metabolismo , Unión Proteica , Dominios y Motivos de Interacción de Proteínas , Mapas de Interacción de Proteínas , Recombinasa Rad51/química , Proteínas Supresoras de Tumor/química , Proteínas Supresoras de Tumor/metabolismo
14.
Neoplasma ; 60(4): 432-8, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23581416

RESUMEN

OBJECTIVES: The microRNA 142 (miR-142) is expressed at high levels in mature hematopoietic cells and has a crucial role during T-lymphocyte development. Its role in leukemogenesis is unclear. PATIENTS AND METHODS: Expression of miR-142 was analyzed in acute myeloid and lymphoblastic leukemia cells (de novo, cell lines). Data were compared to expression in CD34+ hematopoietic cells. Based on the miR-142 expression, clinical data such as overall survival was analyzed. RESULTS: MiR-142 expression in all leukemia cell lines and 86 % of the de novo samples was higher than in CD34+ cells. This difference could be detected in both, myeloid and lymphoid neoplastic cells. In AML patients with intermediate cytogenetic risk a high miR-142 expression was associated with a better overall survival. CONCLUSIONS: MiR-142 expression in acute lymphoblastic as well as myeloid leukemia cells is higher than in CD34+ cells. Additionally, miR-142 expression might have prognostic relevance in AML-patients with otherwise an intermediate cytogenetic risk.


Asunto(s)
Leucemia Mieloide Aguda/genética , MicroARNs/análisis , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Adulto , Anciano , Anciano de 80 o más Años , Línea Celular Tumoral , Femenino , Humanos , Leucemia Mieloide Aguda/mortalidad , Masculino , MicroARNs/fisiología , Persona de Mediana Edad , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Pronóstico
15.
Bone Marrow Transplant ; 48(7): 922-5, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23318540

RESUMEN

The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34(+) stem cells of healthy donors (HD). In 2008, the G-CSF biosimilar XM02 (Ratiograstim, Tevagrastim and Biograstim) was approved by the European Medicines Agency (EMA) for the mobilization of PBSC. However, there is limited experience in the application of biosimilar G-CSF for the mobilization of PBSC especially in HD. Therefore, we investigated in two cohorts (n=22), the efficacy and safety of PBSC mobilization by either biosimilar G-CSF or reference G-CSF. We observed a similar yield of CD34(+) stem cells as well as CD3(+) T-cells and nucleated cells in both groups and a safe engraftment in all patients with similar reconstitution of hematopoiesis in all hosts. In summary, we found a comparable efficacy and safety of biosimilar G-CSF when compared with reference G-CSF.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Movilización de Célula Madre Hematopoyética/métodos , Leucemia/terapia , Linfoma no Hodgkin/terapia , Trasplante de Células Madre de Sangre Periférica , Donante no Emparentado , Adulto , Anciano , Antígenos CD34/metabolismo , Estudios de Cohortes , Femenino , Filgrastim , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos
16.
Bone Marrow Transplant ; 48(1): 129-34, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22609882

RESUMEN

The influence of personality on health related quality of life (QoL) and physical functioning in the setting of allogeneic hematopoietic SCT (alloHSCT) is unknown. We conducted a joint evaluation within two independent cohorts of alloHSCT recipients to investigate the impact of personality on reported QoL and physical functioning. Two-hundred-eight patients (median age 44 years, range 18-72) of cohort 1 and 93 patients (median age 55 years, range 19-79) of cohort 2 after alloHSCT were evaluated. Personality was assessed using the 24-adjective measure (AM), which measures the Big-Five personality domains and the Life Orientation Test-Revised (LOT-R), measuring optimism and pessimism. QoL was measured using the Functional Assessment of Cancer Therapy with bone marrow transplantation subscale (FACT-BMT), Short Form 36 (SF-36), the human activity profile (HAP), as well as the NIH criteria-based cGVHD activity assessment form and the Lee cGVHD symptom scale. Neuroticism was significantly associated with worse function measured by the HAP and FACT-BMT. Optimism significantly improved QoL captured by the FACT-BMT. Pessimism significantly impaired physical function captured by the HAP and SF-36. Extraversion was significantly associated with reduced depression and lower severity of cGVHD symptoms reported by the patient and the physician. The results suggest that personality traits and pre-treatment QoL assessments should be measured in clinical trials to facilitate the interpretation of QoL data.


Asunto(s)
Enfermedad Injerto contra Huésped/psicología , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas/psicología , Trastornos de la Personalidad/psicología , Personalidad , Calidad de Vida , Actividades Cotidianas , Adolescente , Adulto , Anciano , Trastornos de Ansiedad/complicaciones , Trastornos de Ansiedad/psicología , Austria , Estudios de Cohortes , Estudios de Seguimiento , Alemania , Enfermedad Injerto contra Huésped/complicaciones , Enfermedad Injerto contra Huésped/fisiopatología , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/psicología , Humanos , Estudios Longitudinales , Persona de Mediana Edad , Neuroticismo , Trastornos de la Personalidad/complicaciones , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Trasplante Homólogo , Washingtón , Adulto Joven
17.
Eur J Nutr ; 52(3): 1223-31, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22872323

RESUMEN

PURPOSE: Diets rich in plant-derived polyphenols such as olive oil (OO) and/or catechins such as epigallocatechin 3-gallate (EGCG) have been shown to reduce the incidence of cardiovascular diseases, potentially by improving endothelial function, an important surrogate for atherosclerosis. The possible augmentation of endothelial function with the combined efforts of OO and EGCG is intriguing, yet unknown. METHODS: Eighty-two patients with early atherosclerosis (presence of endothelial dysfunction) were enrolled in this double-blind, randomized trial with 52 completing the study. The aim of the study was to compare the effect of a daily intake of 30 ml simple OO, with 30 ml of EGCG-supplemented OO, on endothelial function as well as on inflammation and oxidative stress after a period of 4 months. Endothelial function was assessed noninvasively via peripheral arterial tonometry (Endo-PAT®). RESULTS: After 4 months, when OO and EGCG-supplemented OO groups were combined, OO significantly improved endothelial function (RHI, 1.59 ± 0.25-1.75 ± 0.45; p < 0.05). However, there were no significant differences in results between the two olive oil groups. Interestingly, with OO supplementation there was a significant reduction in inflammatory parameters: sICAM (196 to 183 ng/mL, p = < 0.001); white blood cells (WBCs) (6.0 × 109/L-5.8 × 109/L, p < 0.05); monocytes (0.48 × 109/L to 0.44 × 109/L, p = 0.05); lymphocytes (1.85 × 109/L to 1.6 × 109/L, p = 0.01); and platelets (242-229 × 109/L, p = 0.047). CONCLUSIONS: Improvement in endothelial dysfunction in patients with early atherosclerosis in association with significant reduction in leukocytes may suggest an important role of early cellular inflammatory mediators on endothelial function. The current study supports one potential mechanism for the role of olive oil, independent of EGCG, modestly supplemented to a healthy cardiovascular diet.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/uso terapéutico , Aterosclerosis/dietoterapia , Endotelio Vascular/fisiopatología , Alimentos Fortificados , Aceites de Plantas/uso terapéutico , Polifenoles/uso terapéutico , Adulto , Antiinflamatorios no Esteroideos/efectos adversos , Antioxidantes/efectos adversos , Aterosclerosis/inmunología , Aterosclerosis/fisiopatología , Camellia sinensis/química , Dieta Mediterránea , Método Doble Ciego , Endotelio Vascular/inmunología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Minnesota , Aceite de Oliva , Estrés Oxidativo , Pacientes Desistentes del Tratamiento , Hojas de la Planta/química , Aceites de Plantas/efectos adversos , Polifenoles/efectos adversos , Índice de Severidad de la Enfermedad
18.
Clin Dev Immunol ; 2012: 146463, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22719778

RESUMEN

Leukemic blasts overexpress immunogenic antigens, so-called leukemia-associated antigens like the receptor for hyaluronan acid-mediated motility (RHAMM). Persistent RHAMM expression and decreasing CD8+ T-cell responses to RHAMM in the framework of allogeneic stem cell transplantation or chemotherapy alone might indicate the immune escape of leukemia cells. In the present study, we analyzed the expression of RHAMM in 48 patients suffering from acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Furthermore, we correlated transcripts with the clinical course of the disease before and after treatment. Real-time quantitative reverse transcriptase polymerase chain reaction was performed from RNA of peripheral blood mononuclear cells. T cell responses against RHAMM were assessed by tetramer staining (flow cytometry) and enzyme-linked immunospot (ELISPOT) assays. Results were correlated with the clinical outcome of patients. The results of the present study showed that almost 60% of the patients were RHAMM positive; specific T-cells recognizing RHAMM could be detected, but they were nonfunctional in terms of interferon gamma or granzyme B release as demonstrated by ELISPOT assays. Immunotherapies like peptide vaccination or adoptive transfer of RHAMM-specific T cells might improve the immune response and the outcome of AML/MDS patients.


Asunto(s)
Proteínas de la Matriz Extracelular/inmunología , Receptores de Hialuranos/inmunología , Leucemia Mieloide Aguda/inmunología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Proteínas de la Matriz Extracelular/genética , Femenino , Expresión Génica , Trasplante de Células Madre Hematopoyéticas , Humanos , Receptores de Hialuranos/genética , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/terapia , Masculino , Linfocitos T Citotóxicos/inmunología , Transcripción Genética
19.
Klin Padiatr ; 224(3): 132-8, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22504776

RESUMEN

Fanconi anemia (FA) is a rare recessive DNA repair disorder that is clinically characterized by congenital malformations, progressive bone marrow failure, and increased incidence of malignancies, especially acute myeloid leukemia and squamous cell carcinomas of the head and neck (HNSCCs) and the anogenital regions. On a cellular level, typical features of the disorder are a high degree of genomic instability and an increased sensitivity to bi-functionally alkylating agents. So far, germ-line defects in 15 different FA genes have been identified. Some of these FA genes are also established as tumor susceptibility genes for familiar cancers.In recent years, the prevention and therapy of HNSCCs in FA patients has become more important as the percentage of patients surviving into adulthood is rising. HNSCCs appear in very young FA patients without common risk factors. Since cisplatin-based chemotherapy in combination with radiotherapy, essential parts of the standard treatment approach for sporadic HNSCCs, cannot be used in FA patients due to therapy-associated toxicities and mortalities even with reduced dosing, surgery is the most important treatment option for HNSCCs, in FA patients and requires an early and efficient detection of malignant lesions. So far, no uniform treatment protocol for the management of HNSCCs in FA patients exists. Therefore, we propose that the information on affected FA patients should be collected worldwide, practical therapeutic guidelines developed and national treatment centers established.


Asunto(s)
Carcinoma de Células Escamosas/epidemiología , Anemia de Fanconi/epidemiología , Neoplasias de Cabeza y Cuello/epidemiología , Neoplasias de Oído, Nariz y Garganta/epidemiología , Algoritmos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/terapia , Quimioradioterapia , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Terapia Combinada , Estudios Transversales , Diagnóstico Precoz , Anemia de Fanconi/diagnóstico , Anemia de Fanconi/genética , Predisposición Genética a la Enfermedad/genética , Mutación de Línea Germinal , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/genética , Neoplasias de Cabeza y Cuello/terapia , Humanos , Incidencia , Tamizaje Masivo , Neoplasias de Oído, Nariz y Garganta/diagnóstico , Neoplasias de Oído, Nariz y Garganta/genética , Neoplasias de Oído, Nariz y Garganta/prevención & control , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/genética , Infecciones por Papillomavirus/terapia , Guías de Práctica Clínica como Asunto , Factores de Riesgo , Carcinoma de Células Escamosas de Cabeza y Cuello , Resultado del Tratamiento
20.
Cell Tissue Res ; 348(1): 29-35, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22362508

RESUMEN

Apart from the well-known biologically active angiotensin II, other biologically active angiotensins have been discovered, including angiotensin IV and angiotensin-(1-7). Some years ago, we and others discovered that the Mas proto-oncogene encodes a receptor that is essential for angiotensin-(1-7) signaling. Angiotensin-(1-7) is not only expressed in the periphery but also within the brain. Based on that, we examined the distribution of Mas within the murine brain, using an antibody directed against the 3(rd) cytoplasmic loop of the receptor protein. Strongest Mas protein expression was detected in the dentate gyrus of the hippocampus and within the piriform cortex. However, Mas protein expression is not restricted to these areas, since Mas immunopositive neurons were also seen in different parts of the cortex, hippocampus, amygdala, basal ganglia, thalamus and hypothalamus. Based on the expression of Mas protein in the cortex and the limbic system, angiotensin-(1-7) signaling may play a role in synaptic plasticity, learning, memory and emotion, as has been described for angiotensin II and IV.


Asunto(s)
Prosencéfalo/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Animales , Animales Recién Nacidos , Inmunohistoquímica , Indoles/metabolismo , Masculino , Ratones , Especificidad de Órganos , Prosencéfalo/citología , Transporte de Proteínas , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/análisis , Receptores Acoplados a Proteínas G/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA